Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy

NCT00430950 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00430950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00430950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2007
Completion date
October 31, 2008
Enrollment
1,011 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension